You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
透視港股通丨內資持續加倉藥明生物

北水總結

3月24日港股市場,北水成交淨賣出8.16億,其中港股通(滬)成交淨買入2.11億港元,港股通(深)成交淨賣出10.27億港元。

北水淨買入最多的個股是藥明生物(02269)、中國移動(00941)、騰訊(00700)。北水淨賣出最多的個股是華潤啤酒(00291)。

數據來源:盈立智投APP

十大成交活躍股

數據來源:港交所

個股點評

藥明生物(02269)再獲淨買入7.73億港元。消息面上,高盛發佈研報稱,藥明生物去年銷售額按年增長83.3%,較該行預測高出3.3%,純利增長100%,亦略勝高盛預期。雖然投資者對資金投入及市場需求感到擔憂,但高盛認爲,藥明積壓訂單增長強勁,整體及三年積壓訂單分別按年增長20.1%及98.2%。高盛指,藥明管理層一直在積極與美國商務部洽商,料將成爲今年股價的關鍵催化劑,鑑於公司運營的持續強勁及積壓訂單增長進一步鞏固基本面,重申“買入”評級。此外,藥明生物管理層透露與美國、歐盟、日本和中國客戶簽訂了11個新的綜合項目,表明其業務或客戶沒有受到UVL的影響。

中國移動(00941)獲淨買入3.69億港元。消息面上,中國移動公佈2021年業績,營運收入爲人民幣8483億元,同比增長10.4%,收入增速創10年新高;股東應佔利潤爲人民幣1161億元,同比增長7.7%。瑞銀表示,中移動業績穩健、派息增加,提升股東回報,目標價由75港元上調至80港元。該行認爲,中國移動派息有驚喜,2021年派息率達利潤的60%,公司目標自2021年起三年內,以現金方式分配的利潤逐步提升至當年公司股東應佔利潤的70%以上。值得注意的是,同屬電信股的中國電信(00728)獲淨買入9194萬港元。

騰訊(00700)績後重挫近6%,部分北水資金逢低吸籌,全天淨買入額達3.46億港元。消息面上,大和發表研報指,騰訊去年第四季業績令人失望,主要由於旗下遊戲及廣告業務收入增長疲軟,公司預計今年下半年將改善。 該行指,由於下調對騰訊遊戲及廣告收入預期,對其2022至2023年收入預測下調2%,重申“買入”投資評級,將目標價由600港元降至580港元,此按綜合方式作估值。 該行預期,由於未成年人的遊戲時間顯著減少,去年第四季至今年第三季線上遊戲收入將錄得中單位數的跌幅,相信遊戲版號暫停審批對行業的影響將延續到2023年。

中海油(00883)獲淨買入5071萬港元。消息面上,美國石油協會(API)公佈數據顯示,截至3月18日當週,原油庫存減少428萬桶,汽油庫存減少62.6萬桶,精煉油庫存減少82.6萬桶,庫欣原油庫存增加64.6萬桶。美國銀行認爲,隨着WTI合約每月到期,出現空頭擠壓的風險增加,同時,WTI原油相對於其他北美等級原油走強以鼓勵更多原油流向庫欣樞紐的風險也會增加。花旗此前發佈研報稱,在油價上漲的環境下,中海油是“三桶油”中的主要受益者,因爲中海油爲純上遊企業,原油產量佔總產量的80%。

華潤啤酒(00291)遭淨賣出1.01億港元。消息面上,華潤啤酒午間公佈年度業績,集團實現營業額333.87億元,同比增長6.2%;未計利息及稅項前盈利59.91億元,同比增長94.6%;股東應佔綜合溢利45.87億元,同比增長119.1%,不及早前發盈喜時預測純利44億至47億元的上限。此外,華潤啤酒首席執行官侯孝海在全年業績記者會上表示,去年下半年業務表現較上半年差,主要由於疫情反覆,嚴格防控措施抑制啤酒消費影響盈利水平,對今年行業前景審慎樂觀。

此外,融創中國(01918)獲淨買入7828萬港元。

港股通最新持股比例排行

(港股通持股比例排行,交易所數據T+2日結算)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account